MedTrace Logo

Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer

NCT04749407 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-02-11

No results posted yet for this study

Summary

This study aims to dynamically monitor the expression profile status of peripheral blood mononuclear cells (PBMC) and the changes in circulating tumor DNA (ctDNA) levels in patients with stage III locally advanced unresectable non-small-cell lung cancer(NSCLC) after concurrent chemoradiotherapy or sequential chemoradiotherapy, and to explore biomarkers related to the immune microenvironment and the optimal time point for immunotherapy after chemoradiotherapy.

Conditions

  • Non-small Cell Lung Cancer Stage III

Interventions

GENETIC

biomarker detection

PBMC and ctDNA analysis

Sponsors & Collaborators

  • First People's Hospital of Hangzhou

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-28
Primary Completion
2022-07-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04749407 on ClinicalTrials.gov